Literature DB >> 10757395

Diffuse-type giant cell tumor: clinicopathologic and immunohistochemical analysis of 50 cases with extraarticular disease.

N S Somerhausen1, C D Fletcher.   

Abstract

The clinical and pathologic features of 50 cases of diffuse-type tenosynovial giant cell tumor (D-TGCT), also known as extraarticular pigmented villonodular tenosynovitis (PVNTS), are presented. Patients' ages ranged from 4 to 76 years (median, 41 yrs), with a slight female predominance (28 women, 22 men). By definition, all lesions presented as predominant soft tissue masses, with or without an associated articular component. Tumor sites included the wrist (9 cases), knee (8 cases), thigh and foot (6 cases each), finger (5 cases), ankle (3 cases), hand, elbow, toes, buttock, paravertebral region (2 cases each), lower leg, sacrococcygeal area, and retroperitoneum; 27 cases were described as entirely extraarticular. Tumors showed infiltrative margins and, in most cases, a sheet-like growth pattern. Striking variation in the number of osteoclast-like giant cells, foamy cells, amount of hemosiderin, and in the degree of stromal hyalinization were responsible for a wide morphologic spectrum. In addition to the predominant histiocyte-like cells, we identified in most cases a subpopulation of large dendritic, desmin-positive cells showing characteristic, but potentially misleading, cytologic features, including abundant eosinophilic cytoplasm, large vesicular nuclei, paranuclear eosinophilic inclusions, and occasional nuclear inclusions. Follow-up information was available for 24 patients, with a duration ranging from 6 months to 30 years (mean, 55 mos). Local recurrence occurred in eight cases (33%), between 4 months and 6 months after surgery (median, 15 mos) and was repeated in five cases; recurrence did not appear to correlate with morphologic parameters. Six cases showed atypical histologic features and four of these contained areas of sarcomatous change. Among the latter, one of three cases with available follow up developed pulmonary metastases and died after 35 months. In addition, one histologically benign lesion gave rise, after two local recurrences, to inguinal and iliac lymph node metastases. Despite this exceedingly uncommon event, we think most cases of D-TGCT are best regarded as benign but locally aggressive neoplasms with significant recurrent potential and should be treated, when possible, by wide excision. Atypical features such as increased mitotic activity, necrosis, spindling of the mononucleate cells, and cytologic atypia are not indicative of malignancy when present individually. This study also confirms the existence of malignant tenosynovial giant cell tumors, some of which are characterized by aggressive behavior.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10757395     DOI: 10.1097/00000478-200004000-00002

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  44 in total

1.  Intramuscular diffuse-type giant cell tumor within the hamstring muscle.

Authors:  Tatsuya Yoshida; Akio Sakamoto; Kazuhiro Tanaka; Yukihide Iwamoto; Yoshinao Oda; Teiyu Izumi; Masazumi Tsuneyoshi
Journal:  Skeletal Radiol       Date:  2006-07-19       Impact factor: 2.199

2.  Tenosynovial giant cell tumor and pigmented villonodular synovitis: a proposal for unification of these clinically distinct but histologically and genetically identical lesions.

Authors:  Brian P Rubin
Journal:  Skeletal Radiol       Date:  2007-04       Impact factor: 2.199

3.  Nonsurgical giant cell tumour of the tendon sheath or of the diffuse type: are MRI or 18F-FDG PET/CT able to provide an accurate prediction of long-term outcome?

Authors:  Laurent Dercle; Roland Chisin; Samy Ammari; Quentin Gillebert; Monia Ouali; Cyril Jaudet; Jean-Pierre Delord; Lawrence Dierickx; Slimane Zerdoud; Martin Schlumberger; Frédéric Courbon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-11-01       Impact factor: 9.236

4.  Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717-454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor.

Authors:  Swati Sikaria; Josefine Heim-Hall; Elizabeth H Diaz; Ronald Williams; Kamelesh Sankhala; Brenda Laabs; Monica Mita
Journal:  Target Oncol       Date:  2013-02-21       Impact factor: 4.493

5.  Intramuscular Tenosynovial Giant Cell Tumor, Diffuse-Type.

Authors:  Yoo Jin Lee; Youngjin Kang; Jiyoon Jung; Seojin Kim; Chul Hwan Kim
Journal:  J Pathol Transl Med       Date:  2016-01-11

6.  Tenosynovial Giant Cell Tumor of Diffuse Type Mimicking Bony Metastasis Detected on F-18 FDG PET/CT.

Authors:  Kyoung Jin Chang; Byung Hyun Byun; Han Sol Moon; Jihyun Park; Jae Soo Koh; Byung Il Kim; Sang Moo Lim
Journal:  Nucl Med Mol Imaging       Date:  2014-04-23

7.  Extra-Articular Diffuse Giant Cell Tumor of the Tendon Sheath: A Report of 2 Cases.

Authors:  Olga D Savvidou; Andreas F Mavrogenis; Vasilios I Sakellariou; George D Chloros; Thomas Sarlikiotis; Panayiotis J Papagelopoulos
Journal:  Arch Bone Jt Surg       Date:  2016-06

8.  Arthroscopic excision of giant cell tumor of the tendon sheath in the knee mimicking patellar tendinopathy: A case report.

Authors:  Kai Gao; Jiwu Chen; Shiyi Chen; Yunxia Li
Journal:  Oncol Lett       Date:  2016-04-07       Impact factor: 2.967

9.  Malignant giant cell tumor in the carpal tunnel: a case report and review of literature.

Authors:  Carla I J M Theunissen; Johannes Bras; Krijn P van Lienden; Miryam C Obdeijn
Journal:  J Wrist Surg       Date:  2013-08

10.  Diffusion-weighted imaging of soft tissue tumors: usefulness of the apparent diffusion coefficient for differential diagnosis.

Authors:  Shuji Nagata; Hiroshi Nishimura; Masafumi Uchida; Jun Sakoda; Tatsuyuki Tonan; Kouji Hiraoka; Kensei Nagata; Jun Akiba; Toshi Abe; Naofumi Hayabuchi
Journal:  Radiat Med       Date:  2008-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.